Effect of Mirabegron on Intraocular Pressure in Patients with Glaucoma

Objective: Assessment of the effects of mirabegron treatment used for overactive bladder (OAB) symptoms in glaucoma patients on intraocular structures. Materials and Methods: One hundred-twenty six female glaucoma patients, who received mirabegron treatment for OAB symptoms between January 2017 and January 2018, were included in the study. One hundred-twenty female glaucoma patients were chosen as controls. The mean age of the patients in the study and control groups was 46.74 and 44.42, respectively. A daily single dose of 50 mg mirabegron was prescribed for OAB treatment. Intraocular pressure (IOP) was assessed in 4th and 12th weeks in both groups. In the beginning of the treatment period, the mean IOP was 15.20 (+/- 3.20) mmHg in the study group and 15.70 (+/- 4.20) mmHg in controls. Results: The mean IOP in the study group was 15.80 (+/- 3.80) mmHg and 16 (+/- 4.20) mmHg on the 4th and 12th weeks, respectively. The mean IOP controls was 15.60 (+/- 4.80) and 15.80 (+/- 3.20) mmHg on the 4th and 12th weeks, respectively. No significant difference was found on the 4th and 12th weeks of treatment between the groups in terms of intraocular pressure. Conclusion: Mirabegron treatment used for OAB does not affect IOP in patients treated for primary open-angle glaucoma.